340B Drug Pricing Program
The AHA today urged the Department of Health and Human Services to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have access to the program despite changes in their payer mix as a result of the COVID-19 public health emergency.
Motion and Memorandum in Support of Motion to Intervene NOVO NORDISK v Cochran (March 2, 2021)
AHA urges the Department of Health and Human Services (HHS) to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have access to the program despite changes in their payer mix as a result of the COVID-19 public health emergency (PHE).
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY
Government’s Opposition to Motion to Intervene - AstraZeneca v. Cochran (March 12, 2021)
AstraZeneca’s Opposition to Motion to Intervene (March 12, 2021) Insert
Associations’ Reply in Support of Motion to Intervene - AstraZeneca v. Cochran (March 19, 2021)
American Hospital Association, 340B Health, America’s Essential Hospitals, Association of American Medical Colleges, National Association of Children’s Hospitals d/b/a Children’s Hospital Association, and American Society of HealthSystem Pharmacists (collectively the “Proposed Intervenors”) move…
Response to Motion to Intervene - SANOFI-AVENTIS vs HHS (March 22, 2021)